Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE COMPLETES FIRST-IN-HUMAN DOSING IN EXPLORATORY TRIAL OF AI-DRIVEN NON-OPIOID PAIN CANDIDATE ISM9528

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Insilico Medicine has completed the first-in-human dosing of ISM9528, a potential first-in-class non-opioid pain candidate discovered in Abu Dhabi, just four months after its preclinical candidate (PCC) nomination.

The exploratory trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered ISM9528 in a healthy adult volunteer. As the study proceeds, Insilico Medicine may submit additional dossiers to the relevant authorities and expand this exploratory trial, subject to regulatory authorization.

About ISM9528

ISM9528 was nominated as a PCC in July 2026 by Insilico Medicine's Abu Dhabi team, becoming the Company's 31st PCC since 2021 and the second PCC to emerge from its UAE research effort. In preclinical studies, ISM9528 demonstrated favorable efficacy compared to standard of care in validated models of acute postsurgical pain and neuropathic pain, as a potential oral treatment. Moreover, comprehensive *in vitro* and *in vivo* safety screenings across multiple panels and animal models demonstrated favorable safety properties, while rapid systemic absorption and excellent blood-brain barrier permeability support a favorable DMPK profile.

Forward-looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, November 17, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.